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Abstract 
Xpert MTB/RIF assay is a molecular technique which detects Mycobacterium tuberculosis (MTB) and 
rifampicin resistance simultaneously in two hours. Based on the probes cycle threshold (Ct), the assay provides 
a semi-quantitative MTB detection which is the number of polymerase chain reaction (PCR) cycles required to 
amplify MTB deoxyribonucleic acid (DNA) to a level which can be detected. MTB detection is reported as High, 
Medium, Low or Very Low, while rifampicin resistance is reported as detected, not detected or indeterminate. 
Rifampicin resistant results with low or very low MTB detection grade or indeterminate rifampicin resistant 
results should be confirmed with a gold standard culture based drug susceptibility testing (DST).  
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1. Introduction 
Gene-Xpert MTB/RIF assay is a molecular test which is automated and cartridge based, it detects presence of 
Mycobacterium tuberculosis (MTB) and rifampicin resistance simultaneously [1].  
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The assay employs real time polymerase chain reaction (PCR).The reagent for DNA extraction, PCR 
amplification, internal controls and the five partially overlapping fluorescent probes A to E which target the 
rifampicin resistance determining region of MTB  rpoB gene are all contained in a single use cartridge[1].   
Based on the probes cycle threshold (Ct), the assay provides a semi-quantitative MTB detection which is the 
number of PCR cycles required to amplify MTB DNA to a level which can be detected [2]. The results for MTB 
detection is reported as High (Ct< 16), Medium (Ct 16-22), Low (Ct 22-28) or Very low (Ct >28) [2]. In 
samples where rifampicin is susceptible all the five probes exactly match to the PCR amplified MTB DNA and 
their Ct values are the same [2-3]. When there are mutations in the rpoB gene the hybridization dynamics 
change between the amplicon and the probes, this causes a difference between the Ct values of the probes [3]. 
Rifampicin resistant results with low or very low   MTB detection grade should be confirmed with a gold 
standard culture based drug susceptibility testing (DST) [4]. 
2. Case Study 
A 32 year old Kenyan Man consulted a physician for persistent cough of two weeks that was associated with 
night sweats, fatigue, marked weight loss and fevers. His serological status for HIV was positive and hepatitis B 
surface antigen negative, the full blood count was normal and had no history of TB treatment previously. Vital 
signs on examination revealed normal blood pressure, pulse, with high fever. Gene-Xpert MTB/RIF assay on 
sputum revealed MTB detected low, rifampicin resistance indeterminate. A repeat test to confirm the rifampicin 
status using an early morning sample revealed MTB detected low, rifampicin resistance detected. Sputum 
sample was collected and sent for culture and drug susceptibility. In the meantime the patient was commenced 
on first line tuberculosis treatment awaiting culture results. The regimen consisted of rifampicin(R) 
(10mg/kg/day), isoniazid (H) (5mg /kg/day), pyrazinamide (Z) (30mg/kg/day), and ethambutol (E) (20mg/kg 
/day). The first two months consisted of (RHZE), with the last four consisting of (RH). The culture and drug 
susceptibility reports obtained showed growth of mycobacteria which was susceptible to rifampicin, isoniazid, 
ethambutol and pyrazinamide. After 6months of treatment the patient totally recovered.   
3. Discussion 
In our patient as in many cases which are HIV positive, the bacillary burden in sputum was low, sputum results 
on the first sample revealed MTB detected low; rif resistance indeterminate while the second sample was MTB 
detected low; rif resistance detected. Both samples had a low bacillary load, which is a feature mostly 
encountered in HIV positive individuals [5-6]. Our patient was HIV positive; hence therefore the low bacillary 
load would be attributed to the positive HIV status. As in many cases described previously of low bacillary load 
and the inconclusive rifampicin susceptibility results the treatment was delayed for two more days for a repeat 
of the indeterminate rifampicin test result. The sample quality was appropriate and symptoms of pulmonary 
tuberculosis were present. No history of exposure to a patient treated for drug susceptible or resistant 
tuberculosis. Bacteriological confirmation was through phenotypic culture and drug susceptibility, which 
confirmed mycobacterium tuberculosis sensitive to streptomycin, isoniazid, rifampicin, ethambutol and 
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pyrazinamide. Other false positive rifampicin results have been reported, Marlowe and his colleagues identified 
a specimen that was repeatedly rifampicin resistant on Xpert but susceptible on phenotypic DST [7]. Also 
Theron and his colleagues identified six rifampicin resistant cases on Xpert, five of which were susceptible on 
phenotypic DST [8]. Culture and phenotypic drug susceptibility testing remains essential, especially in drug 
susceptibility tests involving nucleic acid amplification tests where there are inconclusive results [6].  
4. Recommendations 
The health care personnel need to have in depth knowledge about test performance and interpretation of results; 
also culture and phenotypic drug susceptibility testing should be accessible. 
5. Limitation 
The results of this report can’t be generalized to the wider population 
6. Conclusion 
In conclusion our case emphasizes the importance of culture and phenotypic drug susceptibility testing in 
susceptibility tests involving nucleic acid amplification tests; this is important especially in cases of 
inconclusive results i.e. indeterminate rifampicin test results.  Rifampicin resistant diagnosis in tests with very 
low and low MTB detection grade should   be confirmed with a gold standard culture based DST. 
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